United Therapeutics (NASDAQ:UTHR) CFO James Edgemond Sells 3,517 Shares

United Therapeutics Corporation (NASDAQ:UTHR) CFO James Edgemond sold 3,517 shares of United Therapeutics stock in a transaction dated Monday, December 15th. The stock was sold at an average price of $495.36, for a total transaction of $1,742,181.12. Following the completion of the transaction, the chief financial officer directly owned 8,142 shares of the company’s stock, valued at $4,033,221.12. This trade represents a 30.17% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

James Edgemond also recently made the following trade(s):

• On Monday, December 8th, James Edgemond sold 21,000 shares of United Therapeutics stock. The shares were sold at an average price of $478.60, for a total transaction of $10,050,600.00.
• On Monday, December 1st, James Edgemond sold 21,000 shares of United Therapeutics stock. The stock was sold at an average price of $479.99, for a total transaction of $10,079,790.00.
• On Monday, November 24th, James Edgemond sold 21,000 shares of United Therapeutics stock. The shares were sold at an average price of $473.64, for a total value of $9,946,440.00.
• On Monday, November 17th, James Edgemond sold 21,000 shares of United Therapeutics stock. The stock was sold at an average price of $470.36, for a total value of $9,877,560.00.
• On Monday, November 10th, James Edgemond sold 21,000 shares of United Therapeutics stock. The stock was sold at an average price of $452.07, for a total value of $9,493,470.00.
• On Tuesday, November 4th, James Edgemond sold 21,000 shares of United Therapeutics stock. The shares were sold at an average price of $436.09, for a total value of $9,157,890.00.

United Therapeutics Price Performance

Shares of United Therapeutics stock traded down $0.30 during trading on Tuesday, hitting $500.00. 483,805 shares of the company’s stock traded hands, compared to its average volume of 578,260. United Therapeutics Corporation has a 1 year low of $266.98 and a 1 year high of $502.77. The business has a 50-day simple moving average of $458.75 and a 200-day simple moving average of $376.11. The stock has a market capitalization of $21.53 billion, a P/E ratio of 18.95, a PEG ratio of 4.90 and a beta of 0.86.

United Therapeutics (NASDAQ:UTHR) last posted its earnings results on Wednesday, October 29th. The biotechnology company reported $7.16 earnings per share (EPS) for the quarter, beating the consensus estimate of $6.89 by $0.27. The business had revenue of $799.50 million for the quarter, compared to analysts’ expectations of $812.87 million. United Therapeutics had a net margin of 40.65% and a return on equity of 18.83%. The business’s revenue for the quarter was up 6.8% compared to the same quarter last year. During the same quarter in the prior year, the business earned $6.39 EPS. On average, equities analysts predict that United Therapeutics Corporation will post 24.48 earnings per share for the current fiscal year.

Institutional Investors Weigh In On United Therapeutics

A number of hedge funds have recently modified their holdings of the business. Chung Wu Investment Group LLC purchased a new stake in shares of United Therapeutics in the 2nd quarter worth $29,000. WealthCollab LLC grew its holdings in United Therapeutics by 55.9% during the second quarter. WealthCollab LLC now owns 106 shares of the biotechnology company’s stock valued at $30,000 after purchasing an additional 38 shares during the period. Rakuten Securities Inc. increased its position in United Therapeutics by 76.7% in the second quarter. Rakuten Securities Inc. now owns 106 shares of the biotechnology company’s stock worth $30,000 after buying an additional 46 shares in the last quarter. SVB Wealth LLC purchased a new stake in United Therapeutics in the first quarter worth about $32,000. Finally, Wilmington Savings Fund Society FSB raised its stake in shares of United Therapeutics by 125.6% in the third quarter. Wilmington Savings Fund Society FSB now owns 88 shares of the biotechnology company’s stock worth $37,000 after buying an additional 49 shares during the period. Institutional investors own 94.08% of the company’s stock.

Analyst Ratings Changes

A number of research analysts recently weighed in on the stock. Weiss Ratings restated a “buy (b-)” rating on shares of United Therapeutics in a research report on Monday, December 8th. Royal Bank Of Canada boosted their target price on shares of United Therapeutics from $569.00 to $587.00 and gave the company an “outperform” rating in a research note on Thursday, October 30th. HC Wainwright raised their price target on United Therapeutics from $500.00 to $525.00 and gave the stock a “buy” rating in a research note on Thursday, October 30th. Cantor Fitzgerald lifted their price objective on United Therapeutics from $405.00 to $525.00 and gave the stock an “overweight” rating in a report on Wednesday, September 10th. Finally, UBS Group increased their target price on United Therapeutics from $580.00 to $600.00 and gave the company a “buy” rating in a report on Thursday, November 6th. Eight research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, United Therapeutics has a consensus rating of “Moderate Buy” and a consensus price target of $505.00.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.